Eli Lilly reported strong third-quarter results with a 39% increase in revenue to $24.4 billion, fueled by successful drug franchises like Mounjaro and Zepbound. The company’s growth is becoming more diversified with new products such as Foundayo, Retatrutide, and the Medicare Bridge program contributing to future revenue potential. Management raised the full-year 2026 revenue forecast by $5.5 billion, although the stock’s valuation remains high, reflecting risks from pricing pressures and the need to meet elevated growth expectations.
Eli Lilly's stock price at USD 1,396.23 shows a 1.69% gain as of Oct 30, 2026, 16:51 WIB, contrasting with its relatively low dividend yield of 0.54%. Despite strong revenue growth and raised forecasts, the market shows a high sell interest with 91% of Pluang orders being sell orders, reflecting cautious sentiment among investors holding the stock for an average of 94 days.
Eli Lilly's stock surged 6% to a record $1.3 trillion valuation after reporting stronger-than-expected earnings driven by sales of weight-loss drugs Mounjaro and Zepbound. Both drugs exceeded sales expectations by over 5%, reinforcing Eli Lilly's dom...
Eli Lilly reported a 38.6% year-over-year revenue increase to $24.4 billion in Q3, driven by strong sales of its diabetes and obesity treatments Mounjaro and Zepbound, which generated $16.08 billion, up 59.1% from last year. Sales of Ebglyss, a treat...
Merck's stock rose 5% following its Q3 2026 earnings report, which beat analyst expectations with adjusted EPS of $2.49 and revenue of $18.09 billion. The company raised its 2026 adjusted EPS guidance to $2.77-$2.82, driven by strong sales of its can...
Eli Lilly reported a record quarter driven by strong sales of its weight-loss injection, Zepbound. The company raised its 2026 revenue outlook for the third time this year, now expecting between $91 billion and $92 billion. This reflects the growing ...
Eli Lilly reported a 39% revenue increase to $24.4 billion in Q3 2026, led by strong sales of Mounjaro and Zepbound. Earnings per share rose 16% to $7.22 on a reported basis, with the company raising its full-year revenue guidance to $91-$92 billion....
